Latest Developments

Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA

Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data

TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1

Methylone: Distinct Pharmacological and Mechanistic Effects Compared with MDMA

Transcend and Yale awarded U.S. Department of Defense grant to study methylone for PTSD

Our story: Letter from Blake Mandell, Co-founder and CEO, to Transcend Investors

Transcend Therapeutics announces Series A funding round of $40 million

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity